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Increased calcitonin plasma concentrations in chronic and early
acute renal failure. R. Ardaillou, R. Isaac, M. Beaujils and M. P.
Nivez. INSERM, (164, Hbpital Tenon, Paris, France. Plasma
calcitonin (CT) and parathyroid hormone (PTH) concentrations
were compared before and after calcium infusion (4.5 g of calcium
gluconate over 12 mm) in both recurrently hemodialyzed patients
and control subjects. Concentrations of both hormones were sig-
nificantly higher in patients with chronic renal failure (mean + SM
= 1.5 + 0.3 and 3.5 0.6 ng/ml for CT and PTH, respectively)
than in control subjects (mean + SEM = 0.15 0.06 and 0.7 + 1
ng/ml for CT and PTH, respectively). In the uremic group, calcium
infusion inhibited PTH secretion but did not affect CT. High
plasma CT levels were also observed in 10 of 11 patients with acute
renal failure particularly in the oliguric phase. A large dispersion
was observed in these patients, plasma CT ranging between 0.98
0.42 and 16.08 0.22 ng/ml (mean + SEM of serial daily samples).
CT levels decreased progressively with time independent of renal
function recovery. High plasma CT values were found whatever
the antiCT antibody used (four different antibodies), and plasma
CT was completely removed using charcoal extraction. Multiples
dilutions of plasma with high CT levels gave a radioimmunoassay
curve superposed to that obtained with synthetic human CT in-
dicating same immunological reactivity of both peptides. Calcium
plasma concentration was inversely correlated to plasma CT levels,
suggesting that hypocalcemia of acute renal failure could be a
consequence of the early rise in CT.
Serial histomorphometric and histochemical bone biopsy studies in
dialysis and transplantation. V. Bonomini, G. Bortolotti, C. Feletti
and M. Scolari. Nephrology Dialysis Dept., St. Orsola Univ. Hospi-
tal, Bologna, Italy. A serial bone biopsy longitudinal study has
been undertaken to assess the effects of dialysis and transplanta-
tion on uremic osteodystrophy. The clinical material consists
of up to 676 bone biopsies in 384 cases, A significant correla-
tion has been documented between duration of low protein diet
and bone changes. In long-term dialysis patients, remarkable
differences have been found in "late" dialysis starting-time (mean
value of creatinine clearance at the beginning of treatment, 2.04
1.7) with respect to "early" starting-time (mean value, 13.1 3.9).
In the late group, bone histomorphometry showed quite evident
signs of secondary hyperparathyroidism and hyperosteoidism
which remarkably worsened three to four years after dialysis. The
amino acid composition of the bone showed an increase in the total
amount of amino acids during dialysis, especially for proline,
hydroxyproline and glycine. In the early group, both basic values
and progression rate of bone lesions were less severe. In trans-
planted patients with good renal function (serum creatinine <1.4
mg/I00 ml) bone histomorphometric analysis showed a rather
rapid disappearance of uremic bone lesions. A significant correla-
tion was found among serum PTH, renal function and bone
histology. On some occasions signs of secondary hyperparathy-
roidism were documented even after 16 months. A good correla-
tion between inactive bone surfaces and immunosuppressive regi-
men was found.
Histological, hormonal, biochemical and radiological evaluation
of vitamin D therapy in osteodystrophic patients on RDT. D. Bran-
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caccio, G. Graziani, J. M. Faccini, G. Banfi, G. Pedoja and L.
Watson. Sezione di Nefrologia e Dialisi, Opesdale Policlinico, Mi-
lano, Italy; University College Hospital Medical School, London,
England; Inst it uto di Radiologia, Ospedale S. Carlo Borromeo, Mi-
lano, Italy; and University College Hospital, London, England. Five
patients of our Unit on long-term RDT showing clinical and
radiological signs of well-established long-standing osteodystrophy
were studied. For almost two years the schedule of RDT was:
Gambro LN 13.5 U, 5 hr >< 3 X week; bath Ca, 8 mg/l00 ml. All
patients were treated with high doses of vit D2 (600,000 U weekly
for six months); at the beginning and at the end of therapy the
patients were checked for blood PTH levels, bone biopsies (eval-
uated by an image analyzing computer), bone X-ray; blood Ca, F,
alkaline phosphatase were estimated weekly. Evident improvement
of PTH levels and X-ray findings were observed after six months of
therapy, continued as far as hypercalcemic crisis appeared. The
results show: high doses of vit D2 can reverse uremic long-standing
osteodystrophy; no ditlérence between anephric and nephric
patients was observed; vascular calcifications seem to improve;
since hydroxylate vit D metabolites are not available, high doses of
vit D2 can be suggested in the treatment of uremic osteodystrophy.
Microtubule disrupters and secretion of parathyroid hormone in
viva J. Chanard, S. Klahr and E. Slaiopolsky. Inserm U.90 Hbpital
Necker, Université Paris, France, and Washington University, St.
Louis, Missouri, U.S.A. Colchicine (C) and vinblastine (V) have
been shown to interfere with the secretory process of several hor-
mones and neuro-transmitters. The inhibitory effect of these drugs
is related to their microtubule-disrupting action. In the para-
thyroid gland (PTG) C and V induce a total disappearance of
microtubules that suggests inhibition of immunoreactive para-
thormone (iPTH) secretion. To investigate this hypothesis we have
measured serum iPTH release three hours after injection of these
drugs, either intraperitoneally (i.p.) or intravenously (iv.). The
decrease in ionized calcium (ICa) and the corresponding increase
in iPTH were:
Group N ICa, mg/100 ml iPTH, pg/mI
Control 12 4.51 0.08 (sEM) 80 + 10
C 2.5 mg/kgi.p. 6 3.09 0.19a 210 25
C 2.5 mg/kg iv. 8 3.61 0.24a 287 + 23a
V 1 mg/kg i.p. 6 4.44 0.05 80 + 12
V 10mg/kg iv. 6 4.20 0.07 257 50a
a P < 0.001.
The increased-iPTH secretion induced by C was suppressed by
calcium gluceptate injection preventing the drop in ICa. Three
hours after injection of C or V, the PTG retained its ability to
secrete more iPTH when stimulated by a further decrease in ICa
induced by disodium EDTA injection. These results indicate that:
1) high doses of C or V induced a decrease in ICa related to a direct
effect at the bone level; 2) iPTH-increased secretion in response to
a decrease in ICa was not suppressed by the microtubule disrupt-
ers; 3) iPTH secretion could be possible without requirement of
tubulin polymerization.
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Defective calcium absorption in the proximal small intestine in
uremic man: Effect of dihydrotachysterol. G. Coen, M. Di Segni, G.
Slirali, and G. A. Cinotti, 2nd Clinica Medica, University of Rome,
Italy. Intestinal absorption of calcium was determined in uremic
patients (GFR, 6 to 20 mI/mm) and in normal controls. Absorp-
tion was evaluated at ten-minute intervals over a four-hour period
after oral administration of radiocalcium in 100 mg Ca. Frac-
tional absorption of the oral dose as a function of time was
calculated by deconvolution from the experimental serum activity
curves obtained following oral and i.v. radiocalcium administra-
tion. In normal subjects intestinal absorption occurred primarily
within the first two hours, with a maximum rate of transport (%
dose/mm) of 0.579 + 0.08 (mean + SE) at about 40 mm after
ingestion of the isotope, while absorption was markedly impaired
in the patients with uremia, the maximum rate of transport being
0.268 + 0.03. At the end of the four-hour period the mean in-
tegrated fractional absorption of the test load in normal controls
and uremic patients was, respectively, 49.9 and 29.9%. Oral adminis-
tration of dihydrotachysterol, 0.66 mg/day for 6 to 10 days, com-
pletely reverses the absorption defect. Absorption was only slightly
improved following administration of 0.33 mg/day. The following
conclusions are presented: 1) Defective calcium transport in uremic
patients appears to be due to impaired absorption in the proximal
part of the small intestine, where a vit D-dependent active trans-
port normally occurs. 2) Dihydrotachysterol reverses the absorp-
tion defect, and its effect is not different from that of 1,25-dihy-
droxycholecalciferol. The activity ratio of these substances
[l,25(OH)2D3/DHT], based on a comparison with published
data on the dihydroxylated compound, is about 1/300—1/600,
3) The present method of study giving detailed information on
proximal intestinal absorption of calcium is preferable to the
mere determination of percent absorption after 24 hr, in estab-
lishing the sensitivity to vit D metabolites and analogues in man
and in defining the dose-effect relationship.
Parathyroidectomy for secondary hyperparathyroidism in chronic
renal insufficiency. J. Corvilain, M. Fuss, P. Kinnaert, J. P. Moer-
mans, C. Toussaint, J. Van Geertruyden and P. Vereerstraeten.
Hbpital Brugman, University of Brussels, Belgium. Among 304
patients hemodialyzed for chronic renal failure, 12 developed
symptoms of secondary hyperparathyroidism (11 under hemo-
dialysis, one before dialysis treatment was undertaken). In-
dications for parathyroidectomy were clinical symptoms (nausea
and vomiting, pruritus, bone pain, joint tenderness and swelling)
and radiologic signs (osteolysis and para-articular calcifications),
biological data (serum Ca, P, alkaline phosphatase and para-
thormone) being of no value. Eleven patients were submitted to
parathyroidectomy. Nine have been followed for at least one year.
In five cases, a subtotal parathyroidectomy was done, leaving a
glandular volume equivalent to one normal parathyroid: these five
patients are cured. In the four other patients, the amount of
parathyroid tissue removed was less important (1+ to 3+ para-
thyroids): one is cured; one is improved; in the two others, who
had not been improved by parathyroidectomy, hyperparathyroid-
ism disappeared after renal transplantation.
Interaction between secondary hyperparathyroidism in uremia and
the beta-adrenergic system at the cardiac level: In vitro and in vivo
studies. T. Drieke, F. Lhoste, A. U/mann, S. Larno, N. K. Man, J.
Zingraff, P. Jungers J. R. Boissier. and J. Crosnier. C.H. U. Necker-
Enfants Malades, Paris, France. I) In vitro study. The effect of
d-l propranolol on isolated guinea pig auricles has been studied
in the presence of hyperparathyroid plasma ultrafiltrates (UF)
sampled in two patients on chronic hemodialysis, before and
after subtotal parathyroidectomy (PTx). The depressant activity of
1.35 X l0- M d-l propranolol on cardiac contractile strength at
five minutes (25.79 + 2.62%, mean + SCM, N = 6) has been found
to be significantly inhibited in the presence of pre PTx-UF (16.26
1.44%, N=6, P<0.0l for patient J. B., and 17.38 0.83%, N=6,
P<0.02 for patient Z. J.). No such inhibition was found in the
presence of post PTx-UF. 2) In vivo study. The effect of isoprotere-
nol (ISO) on cardiac rhythm has been studied in four severely
hyperparathyroid patients on chronic hemodialysis in whom an i.v.
perfusion of ISO was performed before and after PTx. Stepwise
increments of the iv. dose at five-minute intervals were realized
until cardiac rhythm was increased by 20 beats/mm. To obtain this
effect, a mean (range) cumulative dose of 291 (112 to 571) ng/kg
body wt ISO was needed before PTx, whereas it was reduced to 116
(67 to 179) ng/kg body wt after PTx. This difference of cardiac
responsiveness to ISO was observed in the absence of significant
changes in total plasma calcium concentration. 3) In conclusion:
The cardiac effects of d-l propranolol and isoproterenol in the
uremic patient appear to be modified by high plasma para-
thormone concentrations.
Hypercalcemia with oral calcium carbonate in patients on chronic
hemodialysis—Assessment of plasma gastrin and parathyroid hor-
mone. A. Fournier, C. Ferrière, J. Guéris, J. L. Sebert, J. Quichaud
and P. Bordier. CHU d' Amiens and Hbpital Lariboisière, Paris,
France. Unexpected hypercalcemia occurred in four out of ten
patients undergoing chronic hemodialysis with a dialysate calcium
of 6.5 mg/l00 ml. All patients were taking 3.2 g ofCaCO3, 2000 LU
of vitamin D2, 3 g of aluminum hydroxide. Cumulative dose of
vitamin D2 was lower in the hypercalcemic group. Normophospha-
temia was present in 2/6 of the normocalcemic and in 3/4 of the
hypercalcemic patients. In one patient, hypercalcemia promptly
followed lowering of plasma phosphate by aluminum hydroxide.
Increase of CaCO3 in another patient induced a further increase of
plasma calcium (PCa). Discontinuation of CaCO3 was followed by
a prompt return of PCa below 10.0 mg/I00 ml. To investigate the
pathophysiology of the hypercaicemia, plasma concentrations of
parathyroid hormone (PTH) and gastrmn (U) were measured by
radioimmunoassay, and bone biopsies were performed for measur-
ing the active resorption surface. Mean PTH (+ so) was signifi-
cantly lower (P < .05) in the hypercalcemic group than in the
normocalcemic group: 49 (+ 16) vs. 86 (+ 9) ng of protein/mi
(normal range, 4.5 to 9.5). Sequential measurement of PTH and U
in one patient after CaCO3 discontinuation revealed that PCa
was negatively correlated with PTH (r =
—.85, P < .01) and
positively with gastrin (r .77, P<.05). It is concluded that 1) a
moderate oral supplement of CaCO3 may induce severe hypercal-
cemia; 2) phosphate binders may potentiate this hypercalcemic
effect; 3) hyperparathyroidism can be reduced but not completely
suppressed by this chronically induced hypercalcemia and normo-
phosphatemia; 4) a more severe hyperparathyroidism is not the
explanation for the hypercalcemia; 5) hypergastrinemia is the con-
sequence but not the cause of hypercalcemia.
Variation of parathyroid hormone, calcitonin and calcium blood
concentrations in acute renal failure. M. Fuss, E. Dupont, J. Bagon
and J. Corvilain. Université Libre de Bruxelles. Hbpital Brugmann.
Brussels, Belgium. Parathyroid hormone (PTH), creatinine, cal-
cium (Ca) and phosphate (P) blood concentrations were repeatedly
measured in five patients with acute renal failure (ARF), before
hemodialysis and during the recovery phase of the illness. Plasma
calcitonin (CT) was also measured in two of these patients: one of
them developed transient hypercalcemia during the recovery pe-
riod. PTH and CT concentrations were elevated before starting
hemodialysis treatment. After completion of the treatment PTH
and CT varied in parallel to creatinine. In the patient with transient
hypercalcemia there was an inverse correlation between PTC and
Ca concentrations, whereas no relationship was found between TC
and Ca. Our data show that parathyroid function in ARF is closely
related to changes in renal function and that hypercalcemia, wheii
occurring, is not necessarily due to parathyroid hyperactivity.
Nodal calcifications in a patient on chronic maintenance hemo-
dialysis: Survival during 27 months under cardiac pacemaker. C. P.
Giudicelli, T. Kamaludin, Ch. Lombard, P. Larroque, Ch. Hi/ten-
brand and A. Masbernard. Hopital d'Instruction des A rmèes du Va!-
de-Grace, Paris, France. Nodal calcium deposits in a patient on
chronic maintenance hemodiaysis with secondary hyperpar-
athyroidism led the authors to attempt a review of the common
features of the reported cases. Although myocardial calcifications
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could be found on necropsy in 2.5% of the patients with chronic
renal insufficiency, calcium deposits in the conduction system are
seemingly infrequent: only eight cases were found in the literature.
Atrioventricular and/or ventricular conduction disturbances, in
certain cases with atrial fibrillation or ventricular tachycardia,
supervene after a variable duration of hemodialysis (9 to 26
months), following a mostly long-standing renal insufiIciency. In
all the patients an adenomatous or hyperplastic hyperparathyroid-
ism could be pathologically confirmed. In six of them a high
calcium-phosphorous product above 75 had been noted. This re-
ported case is remarkable through the 27 months survival of the
patient under cardiac pacemaker before her death due to gas-
trointestinal bleeding.
A study of the variations of phosphoremia in persons undergoing a
treatment of hemodialysis. B. Guittienne M. Kessler and C. Huriet.
Centre Hospitalier Regional, Nancy, France. From the very begin-
ning of the application of an artificial kidney with an acrylonitrile
membrane (R.P.6 3 X 4 hours/week), a significant increase in
phosphoremia was revealed in the majority of the patients. There
are three possible explanations for this: I) the technique of the
closed circuit (the phosphorus concentration of the dialysate
at the end of the purification process reaches a maximum of 12
mg/liter); 2) the special permeability of the membrane AN 69
with respect to phosphorus; 3) the duration of dialysis treatment.
The same phenomenon is noted if the length of sessions is re-
duced with cuprophan in an open circuit, even if the surface area
is increased in order to maintain the factor m2 per hour per week
constant. Hyperphosphoremia appears therefore to be the result
of a reduction in the length of the sessions of dialysis treatment.
The authors believe that the purification of phosphorus by the
artificial kidney depends neither on the type of dialyzer used
nor on the membrane, but exclusively on the duration of dialysis
treatment; the number of m2 per hour per week plays no part in it.
Heterogeneity of Ca-P regulation in hemodialyzed patients. G.
Heynen, G. Rorive, and P. Franchimont, Dept. of Medicine and
Radioimmunoassay Laboratory, Univ. de Liege, Liege, Belgium.
Fasting serum calcium (Ca), phosphorus (P), alkaline phosphatase
(A.P.), parathyroid hormone (PTI-1) and calcitonin (CT) were
investigated in 42 patients undergoing chronic hemodialysis treat-
ment. The Ca dialysate concentration was 3.75 mEq/liter. As
compared to normal subjects, this population was characterized by
lower Ca and higher P, A.P., PTH and CT levels. However, fre-
quency distribution of these parameters showed a marked hetero-
geneity except for A.P. values, which were clearly distributed in
two populations: normal levels (group 1) and high levels (group 2).
While Ca and P concentrations were not significantly different in
both groups, CT values (mean SEM in ng/ml) were higher in
group 1(2.1 .35) than in group 2 (.64 .1; P<00l), whereas
PTH levels (ng/ml) were higher in group 2 (3.53 .22) than in
group 1(1.19 P<00l). In group I, CT levels was correlated to
PTH, to Ca and to P, and PTH was correlated to P. These correla-
tions were no more apparent in group 2. These results show: I)
Parameters of uremic osteodystrophy are heterogeneously distri-
buted in hemodialyzed subjects. 2) There are at least two popu-
lations, one with normal A.P. and one with high A.P. 3) When
A.P. is normal, Ca-P regulation is achieved in the presence of
higher CT levels and lower PTH levels than when A.P. is high. 4)
The relationship between PTH, Ca or P levels and CT levels is
observed only when A.P. is normal. This heterogeneity should be
taken into account when investigating treatment of "uremic bone
disease."
Quantitative study of bone biopsy in 81 uremic patients. S. Lator-
zeff, D. Durand, D. Durroux, H. Ton That, J. Arlet, J. M, Sue.
Service de Nephrologie, Pavilion Rayer, Hopilal Purpan, Toulouse,
France. A quantitative histological study of iliac bone biopsy is
performed in SI patients with chronic renal failure. Material and
methods. These patients are separated into two groups according to
the serum creatinine levels. Group 1: 14 patients with a mild renal
failure (serum creatinine between 1.8 and 3.5 mg/ 100 ml). Group 2:
67 patients with a more advanced renal failure (serum creatinine
between 6 and 14 mg/lOO ml); 12 of them are maintained on
hemodialysis. Quantitative study is realized with P. Meunier's
technique. In 21 patients previous labeling by demethylchlortet-
racycline is used. Four uncalcified and six non-uncalcifled bone
sections are performed on each biopsy. The six following parame-
ters are studied: bone trabecular volume, resorptive surface, pen-
osteocytic lacunae, relative osteoid volume, osteold surface and
index of osteoid thickness. The latter parameter associated to
calcification front study allows us to distinguish hyperparathyroid-
ism osteoid tissue from osteomalacia osteoid tissue. Results. Group
1: II patients from the first group (mild renal failure) already show
stigmas of slight and alone hyperparathyroidism. Group 2: In the
more advanced renal insufficiency patient group, the two abnor-
malities are found, together or separate. Five patients show ob-
vious and isolated osteomalacia signs. Sixty-two patients show
hyperparathyroidism pattern: in 48 of them hyperparathyroidism
is alone and of various degrees (II most typical hyperparathyroid-
ism, 27 obvious hypcrparathyroidism and 10 mild hyperparathy-
roidism); in 14 others, bone volume increase suggests the addition
of osteomalacia to hyperparathyroidism. The study of these 81
patients leads to the following conclusion: Hyperparathyroidism
stigmas occur commonly (90% of patients) and early, whereas
osteomalacia is seldom seen and associated with the latter in 19%
of patients. Osteomalacia is only found in end-stage renal failure.
Osteomalacia lesions are superimposed secondarily in natural evo-
lution of renal osteodystrophy.
Treatment of severe renal osteodystrophy by 25-hydroxychole-
calciferol. A. Meyrier, Ph. Bordier, c. Pages and R. Ardaillou.
Hbpital Tenon, Paris, France. Four Nondialyzed patients with
chronic renal failure (GRF between 4 and 9 mI/mm) and clinical
and radiological evidence of osteodystrophy were studied. Before
treatment the average serum concentrations for calcium, phosphate
and magnesium were 7.6 mg, 4.5 mg and 2.05 mg/lOO ml, re-
spectively; alkaline phosphatase was 205 IU, parathormone
IPTH) 10.3 ng/ml and calcitonin (CT) zero. Calcium and phos-
phate excretion rates were 49 mg and 415 mg/24 hr. Bone biopsy
showed osteomalacia in all four cases with associated osteoclastic
resorption (moderate in two cases and severe in two). After a
control period of one month on a 500 mg/day calcium diet, 50 sg
of 25-hydroxycholecalciferol (25-OH D3) was given daily for one
month, then increased to 100 pg/day till the end of the study.
Aluminum gels were prescribed whenever the serum phosphate
concentration exceeded 6.0 mg/l00 ml. The following results were
obtained: a moderate rise in serum Ca concentrations (maximum:
8.3 mg/lOU ml) was noted only from week 27 onwards. Serum
phosphate concentrations rose above 6.0 mg/lOO ml at week 25
and were difficult to control with aluminum gels. The calcium and
phosphate excretion rates showed parallel changes. Plasma PTI-l
levels showed three phases: an initial increase until week 12, a fall
between weeks 12 and 17, and then a second larger rise. Serum
magnesium showed similar changes. CT was unmeasurable until
week 12 and then rose rapidly. The alkaline phosphatase levels fell
progressively from week IS onwards, becoming normal at week 30.
The second bone biopsy, performed at the end of the study, showed
osteoid remineralization, reappearance of the calcification front
and diminution of osteoclastic resorption and of fibrosis. We con-
clude that: 1) 25-OH D3 modified favorably the renal Os-
teodystrophy of the patients studied; 2) serum calcium changes
were, however, not pronounced during the treatment period; 3) 25-
OH D3 appears to play an important role in phosphate intestinal
absorption and/or mobilization from bone; 4) variations in PTH
concentrations seem to be linked to concomitant changes in serum
phosphate and/or magnesium concentrations; 5) the reappearance
of CT secretion, not correlated to the serum calcium concentra-
tion, could be an important factor in the diminution of osteoclastic
activity.
Comparative study of the different calcium intestinal absorption
tests: Determination by using a double radiotracer technique with
simultaneous measurement of the urinary excretion rate of calcium.
J. Mirouze and L. Monnier. Department of Endocrinology and
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Metabolism, Hospital Saint-Eloi, Montpellier, France. Fifty-three
determinations of the intestinal absorption rate of radiocalcium
were performed by giving simultaneously two radioisotopes, one
via an oral route (47CaCl2) and the second lv. (45CaCl2). A mathe-
matical procedure of inverse convolution was applied to the time
courses of the oral and iv. plasma activities. By this calculation,
the transit time curve of radiocalcium across the intestinal barrier
was determined and provided an accurate measurement of the total
fractional absorption rate of calcium (TFACa) and of many others
parameters. A good correlation was found between the TFACa
measured by the inverse convolution method and a simple estima-
tion by the oral/i.v. plasma activity quotients. On the contrary a
poor correlation was observed when the 47Ca plasma concentration
at the third hour was plotted vs. the TFACa determined by the
inverse convolution analysis. The TFACa can be measured by
using single radiotracer methods. However, they provide less accu-
racy and information about absorption than the double radio-
tracer technique. By applying this latter method to a group of
seven diabetic patients, we observed that calcium transfers across
the intestinal and renal tubular cells were stimulated by an oral
glucose load. In three primary hyperparathyroidisms, we noted
that intestinal absorption remained elevated a few months after the
patients had been surgically cured.
Interactions between propranolol and the renin-angiotensin sys-
tem. L. Peters-Haefeli and F. J. Kirchertz (introduced by G. Peters).
Institut de pharmacologie de 1' Université de Lausanne, Lausanne,
Switzerland. In pentobarbital-anesthetized rats, D-L-prOpranOlOl
(PR) (0.04 to 5 mg/kg iv.) depressed the basal plasma renin level
(PRL) by 35 to 60%, but did not interfere with the rise of PRL
induced by bleeding. In urethane-anesthetized rats, iv. D-L-PR
(0.25 to 0.50 mg/kg) induced I) an initial rise of blood pressure
(BP) by +14 2 mm Hg lasting Ito 2 mm, 2) a sustained rise of
BP (+7 + 1 mm Hg) lasting for more than 30 mm, and 3) an in-
crease of the pressor potency of val5-angioteiisin II amide (AT II)
by a factor of 2 to 4. These effects were abolished in adrenalectô-
mized rats. D-PR caused an initial rise of BP (1), but neither effects
(2) nor (3). It was concluded that the initial rise of BP (I) is
presumably due to a PR-induced release of catecholamines for the
adrenal medulla, while the increased potency of AT 11(3) is due to
a blockade of vasodilatator beta receptors. Since o-L-PR does not
depress rises of PRL after hemorrhage, and since its depressor
effect on basal PRL would be compensated by an increased re-
sponse to AT II, its antihypertensive action appears to be inde-
pendent of the renin-angiotensin system.
Thyroid lymphography: A new method for preoperative local-
ization of the parathyroid glands and for the study of secondary
hyperparathyroidism in uremic patients. R. Rossi, A. Farina, G. C.
Cairo/i, G. Casartelli, M. I. Quarenghi, M. Dassi, F. Muggli and G.
Co/antonio. Department of Surgery A and Department of Ne-
phrology. S. Anna Hospital, Como, Italy. Thyroid lymphography,
suggested by Tomojuki Kato et al (Anna/s of Surgery, vol. 107, no.
8, March 1974) as a useful method for preoperative localization of
primitive parathyroid adenomas, was performed by the authors on
patients undergoing regular hemodialytic treatment for pre-
operative localization and size evaluation of hyperplastic para-
thyroid glands. Methods: Bilateral injection of contrast liquid (1 to
1.5 ml of Lipiodol Ultrafluid) in thyroidal parenchyma. Roent-
genograms were taken as follows: antero-post and laterolat projec-
tion IS mm, 30 mm, 60 mm, 180 mm and 24 hr after injection of
Lipiodol. Results: Thyroid lymphography was performed on ten
patients showing altered Ca/P metabolism and high concentra-
tions of serum alkaline phosphatase. Some patients showed meta-
static calcifications at X-ray investigation. PTH serum concentra-
tions were determined in all patients. All patients had hyperplastic
parathyroids of various sizes and two of them underwent surgery.
Operative findings confirmed the radiological localization per-
formed with our method. Conclusions: We have shown that thyroid
lymphography is one of the most useful methods for the local-
ization of hyperplastic parathyroids prior to surgery as well as for
the evaluation of secondary hyperparathyroidism in uremic
patients.
Plasma ionized calcium: From sampling to Ion measurement. C.
E. Sachs and A. M. Bourdeau. Laboratoire dExploration Fonction-
nelle chez l'Enfant, Hopital des Enfants Malades, Paris, France.
Ionized calcium evaluation gained recently in both fields of blood
sampling and ion measurement. The main purpose of the described
sampling device and procedure is to ensure a strictly anaerobic
blood handling throughout the process. Blood is sampled with a
double-edged needle into a thermoplastic supple tube placed under
vacuum in a rigid carrying container. After centrifugation the
supple tube is squeezed and heat-sealed just above the red blood
cells—plasma interface with heat-sealing cutters. The upper com-
partment, thus separated, contains the supernatant plasma, which
can be directly fed into the apparatus with the above-mentioned
needle, just by squeezing the supple tube. It can also be stored at
4°C or deep-frozen. The last liquid membrane electrode system
developed (SS-20 ORION model) operates with a 300-zl sample. It
combines several advantages: it works by a discontinous fully
automated procedure, displays the final result in mEq/liter, and
requires simplified maintenance. Nevertheless right now, the
ready-to-use electrodes, expected to last two to three months, have
too short a life span (five days). This represents a last handicap that
has to be overcome. Plasma ionized calcium (anticoagulant:
I0.s/ml sodium heparinate) measured under these conditions in 60
blood donors was found to be of 1.95 + 0.07 mEq/liter.
Cytosol binding of 25-hydroxycholecalciferol and 1,25-dihydroxy-
cholecalciferol in the rat duodenal mucosa. A. U/mann, M Bra,ni, J.
D. Monet, C. Bader and J L. Funck-Brentano. I.N.S.E.R.M. U.90,
Hbpital Necker, Paris, France. In order to study the mechanism
of action of vitamin D metabolites on the intestinal absorption
of calcium, the cytosol binding of labeled 25-hydroxycholecalciferol
(25-OHD3) or I ,25-dihydroxycholecalciferol (1 ,25-(OH)5D3) was
studied in the duodenal mucosa of vitamin D- and calcium-deficient
rats. Sucrose gradient analysis show that 25-OHD and 1,25-
(OH)2D3 bind to a 5.5-6 S protein; nevertheless, whereas a 100-
fold excess of unlabeId 25-OHD3 completely abolishes the binding
of tritiated l,25-(OH)2D3 a similar excess of unlabeled l,25-(Ol-I)2D3
displaces only partially tritiated 25-Ok-ID3 from its binding site. The
quantification of this binding was performed with a dextran-coated
charcoal assay: tritited 25-OHD3 binds with an apparent dis-
sociation constant at 4° of 1.2 X 10 M, and a binding capacity of
6.5 X l0 M/mg of protein; tritiated I,25-(OH)2D3 binds with a
K0 = 2 x l0 M (4°) and a binding capacity of 2.3 X 10l3 M/mg
of protein. Competition experiments with unlabeled sterols show
that neither progesterone nor dexamethasone nor vitamin D5 can
displace tritiated 25-OHD3 or I,25-(OH)2D3 from their binding
sites; they show that when aliquots of cytosol are incubated with
10_B M tritiated 25-OHD5, a 100-fold excess of unlabeled 25-OHD3
displaces the binding by 80%, whereas a similar excess of unlabeled
l,25-(OH)2D3 displaces this binding by only 40%. Conversely,
when aliquots of cytosol are incubated with 10_B M tritiated 1,25-
(OH)5D3, a 100-fold excess of unlabeled I,25-(OH)3D3 displaces the
binding by 66%, whereas the same amount of 25-OHD3 decreases
the binding by 74%. Thus, both 25-OHD3 and l,25-(OH)2D3 bind
to the duodenal cytosol of vitamin D-defiient rats. The binding
capacity for 1,25-(OH)3D3 is lower than that for 25-OHD3. Com-
petition studies and K0 measurements suggest that among the
25-OHD3 binding sites, some are specific for this sterol, and a
small number can bind 1,25-(OH)2D3 with a lower affinity. Kinetic
studies of these sites are in progress; they Will perhaps provide
some information about their functional significance.
Treatment of renal osteodystrophy with high doses of vitamin D5.
R. Verberckmoes, R. Bouillon and B. K. Krempien. A. Z. St. Rafail,
Leuven, Belgium. Thirteen dialyzed patients with renal osteo-
dystrophy were treated with high doses of vit D3. All patients
had one or more of the following radiological signs: subperiostal
and endosteal resorption in several phalanges, ground-glass ap-
pearance of the skull, resorption of the lateral ends of the clavic-
ulae and/or of the symphysis pubis, Looser-Milkman pseudofrac-
tures. Histological examination showed one or more of the
following signs: increased osteoclastic activity4 broadened osteoid
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seams, periosteocytic osteolysis, endosteal and marrow fibrosis.
Serum PTH and serum alkaline phosphatase levels were elevated.
Vit Da was given orally in doses of 15 mg once to thrice weekly.
Al(OH)3 treatment was adjusted to the predialysis P concentration.
The vit D3 treatment was continued until the serum alkaline level
was normal. At this time usually some degree of hypercalcemia was
seen. The total doses of vit D (120 to 2000 mg) and the duration of
the treatment (60 to 450 days) were inversely correlated with the
dialysate calcium concentration (5.6 or 7.5 mg/l00 ml). At the end
of the treatment in all patients a marked improvement or total
disappearance of the radiological abnormalities was observed,
which was confirmed by the histological controls. Serum PTH
levels measured with a N-specific antiserum were normal or nearly
normal; whereas the decrease of PTH levels obtained with a C-
specific antiserum was less pronounced, these values remaining
highly elevated, even in a patient who was successfully trans-
planted after treatment with vit D3. We therefore postulate that the
hypertrophic parathyroid glands continue to secrete inactive PTH
fragments (measured with the C-specific antiserum) even when the
secretion of active PTH (measured with the N-specific antiserum)
was inhibited. During treatment 25 OH-CC levels reached values
between 200 and 500 ng/ml. The t/2 after the end of the treatment
determined in three patients was 40, 63 and 110 days. Adverse
reactions during and after treatment were minimal. Permanent
hypercalcemia necessitated PTX in one patient. Preexisting vascu-
lar calcifications regressed markedly during treatment in two
patients. Long-term results indicate that permanent suppression
of the parathyroid glands was not obtained: serum PTH (measured
with the N-specific antiserum) returned to high levels some months
after the end of the vit D treatment. A recurrence of manifest renal
osteodystrophy was found in two patients within 18 months after
the end of vit D treatment. Massive hypertrophy of the para-
thyroid glands was found on PTX in three patients after vit D
treatment.
Body calcium measurement by a local neutron activation method
using Californium 252 in renal bone disease. P. Zech, A. Guey, Ph.
Leitienne, M. F. Meary, N. Pozet, J. F. Moskovtchenko and J.
Traeger. Clinique de Néphrologie et des Maladies Métaboliques,
Hopital Edouard Herriot, Lyon, France. Uremic bone disease is a
common cause of morbidity in chronic renal failure. However,
current methods used to investigate calcium metabolism do not
allow a precise quantitation of bone changes in patients under-
going chronic hemodialysis. We report the results of a new
method of neutron activation of calcium. Methods: For each acti-
vation, the left hand was exposed to 70 sg of 252Cf, through 10
mm of perplex for 20 mm. The amount of 49Ca produced was
quantitated by counting the hand in a whole body counter with
two I Na crystals of 6 in. X 4 in. and analytical unit during six
periods of 100 see, 30 sec after the end of irradiation. Twenty
normal subjects and thirty patients with end-stage renal disease
(CRF) maintained on chronic dialysis were studied. Results:
Total Ca (left hand), Mean + SD
26.21 g + 3.15
22.95 + 1.81
17.97 + 1.25
14.27 2.90
Standard deviations of the values within each group (1 12%) were
lowered when corrected for body wt (± 10.6%), size (+ 6.7%) or
radiological bone area (± 6.6%). A significant decrease of calcium
content was found in uremic patients, the values depending on the
duration of the dialytic period and the treatment administered (Ca,
vit D, aluminum hydroxide). Local body calcium activation thus
represents a reproducible method for quantitative determination of
body calcium during chronic hemodialysis treatment.
Short-term effect of 1-hydroxy vs. 25-hydroxy vitamin D3 com-
pounds in renal bone disease. J. Zingraff, Ph. Bordier, T. Drueke, N.
K. Man, J. Gueris, P. Jungers and J. Crosnier, Hopital Necker,
Unites U 25, U 18 et U 26 de l'INSERM, Paris, France. Seventeen
patients with end-stage renal failure, thirteen of whom were on
chronic hemodialysis, were treated by synthetic vjtamin D3 ana-
logues for three weeks. The results have been evaluated on the
following criteria: on plasma concentrations of calcium, phos-
phorus, alkaline phosphatase and immunoreactive PTH (iPTH),
and on repeated quantitative bone histology. The 1-hydroxy ana-
logues (la (OH) D3, three cases, and 1-25 (OH)2D3, 3 cases, at a
dose of 5 sg thrice weekly) have a frank effect on serum calcium
that increases and on serum iPTH that decreases. The increased
bone cell activity is expressed mainly by an increase in the resorp-
tion surface and an increased number of osteoclasts; marrow fibro-
sis regresses. The calcification front increases; osteoid volume
decreases or remains unchanged. The 25-hydroxy-analogue, low
dose (5-6 trans 25 (OH) D3, 8 cases, 20 sg thrice weekly), does not
change serum calcium or serum iPTH; bone histology is not modi-
fied uniformly except that the calcification front increases in six out
of the eight patients. Administered at high doses, the 25 (OH) D3
(three cases, 200 sg thrice weekly) increases serum calcium in only
one of the three patients, with serum iPTH lowered in this one. The
calcification front increases in the three patients; the osteoid vol-
ume decreases. The active resorption and the number of osteoclasts
diminish only slightly. Marrow fibrosis decreases in all the three
cases. The interpretation of the results obtained with these diffe-
rent vitamin D3 analogues will be discussed.
Evolutive aspects of renal osteodystrophy in patients on periodic
hemodialysis. P. Zucchelli, M. Fusaroli, L. Fabbri, P. Pavlica, G.
Viglietta, L. Catizone and S. Casanova. Hospital M. Malpighi,
Bologna, Italy. The development of osteodystrophic lesions and the
influence of therapy with calcium, aluminum hydroxide and DHT
was studied in 25 patients on periodic treatment for more than
three years. All patients underwent repeated investigations, includ-
ing percutaneous biopsy of the iliac crest with undecalcified sam-
ples evaluated according to Bordier, X-ray examination of the
skeleton, radiography of the hands with industrial films, bone
densitometry, scanning of the skeleton with 99 mTc-pyrophos-
phate and PTH dosage. Thus: 1) radiological examination reveals
a turn for the worse of the lesions in 24% of the patients and a
delayed appearance of changes of sacro-iliac junctions, of tern-
poromandibular joint and of phenomena of periosteal neostosis; 2)
therapy exerts a beneficial influence over osteomalacic lesions,
while it is not always able to halt the development of osteitic
lesions, which sometimes require parathyroidectomy.
Normal males
Patients CRF
Normal females
Patients CRF
